Graffinity Pharmaceuticals AG
Missing: Graffinity Pharmaceuticals AG's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Graffinity Pharmaceuticals AG's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Graffinity Pharmaceuticals AG Patents
Graffinity Pharmaceuticals AG has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/8/2013 | 8/29/2017 | Clusters of differentiation, Monoclonal antibodies, Immune system, Proteins, Immunology | Grant |
Application Date | 2/8/2013 |
|---|---|
Grant Date | 8/29/2017 |
Title | |
Related Topics | Clusters of differentiation, Monoclonal antibodies, Immune system, Proteins, Immunology |
Status | Grant |
Graffinity Pharmaceuticals AG Frequently Asked Questions (FAQ)
Who are Graffinity Pharmaceuticals AG's competitors?
Competitors of Graffinity Pharmaceuticals AG include EUCODIS Bioscience, Prosarix, 2cureX, Melinta Therapeutics, BrightPath Biotherapeutics and 12 more.
Compare Graffinity Pharmaceuticals AG to Competitors
Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.
De Novo Pharmaceuticals Ltd is a computationally-based drug discovery company focused on small molecule therapeutics. De Novo develops a suite of structure-generating programs called SkelGen. The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ. Ninety-percent of the structures produced by SkelGen is chemically tractable.
Therasis Inc. is a new drug discovery company developing oncology therapeutics for use as single agents or in combination therapy.
CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers.
IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.
InVasc Therapeutics specializes in target-specific drug discovery and has developed a approach to drug discovery that uses molecular structures and an application-based platform that decreases the time and expense of current large-scale "mining"� discovery techniques. The InVasc process is the result of university-based research at Emory University and The Ohio State University.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.